Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan

Drug Metabolism and Disposition

Volumn 33, Issue 12, 2005, Pages 1785-1790

  Fujita, Ken Ichi ^a   Ando, Yuichi ^a   Narabayashi, Masaru ^a   Miya, Toshimichi ^a   Nagashima, Fumio ^a   Yamamoto, Wataru ^a   Kodama, Keiji ^a   Araki, Kazuhiro ^a   Endo, Hisashi ^a   Sasaki, Yasutsuna ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 (4 AMINO 1 PIPERIDINO)CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO] CARBONYLOXYCAMPTOTHECIN; ALPHA NAPHTHOFLAVONE; CAMPTOTHECIN DERIVATIVE; CYTOCHROME P450 3A4; ERYTHROMYCIN; GEFITINIB; IRINOTECAN; KETOCONAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL; SMALL INTESTINE;

CAMPTOTHECIN; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; MIDAZOLAM; QUINAZOLINES;

EID: 28144436318     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.006205     Document Type: Article

References (37)

1. Akabayashi A (1997) Questions raised over release of side-effects data in Japan. Lancet 350:124.
2. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, et al. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124.
3. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, et al. (2001) Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11:1911-1914.
4. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, et al. (2004) United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218.
5. Culy CR and Faulds D (2002) Gefitinib. Drugs 62:2237-2248.
6. Fujita K, Hidaka M, Takamura N, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Yamaguchi M, Ikenoue T, and Arimori K (2003) Inhibitory effects of citrus fruits on cytochrome P450 3A (CYP3A) activity in humans. Biol Pharm Bull 26:1371-1373.
7. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512-1522.
8. Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone and nifedipine. Drug Metab Dispos 31:1108-1116.
9. Gentile DM, Tomlinson ES, Maggs JL, Park BK, and Back DJ (1996) Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277:105-112.
10. Haaz MC, Riche C, Rivory LP, and Robert J (1998a) Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecine] by human hepatic microsomes. Drug Metab Dispos 26:769-774.
11. Haaz MC, Rivory L, Riche C, Vernillet L, and Robert J (1998b) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472.
12. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. J Biol Chem 272:5396-5402.
13. Honig PK, Wortham C, Hull R, Zamani K, Smith JE, and Cantilena LR (1993a) Itraconazol affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 33:1201-1206.
14. Honig PK, Wortham C, Zamani K, Conner DP, Mullin JC, and Cantilena LR (1993b) Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. J Am Med Assoc 269:1513-1518.
15. Honig PK, Wortham C, Zamani K, Mullin JC, Conner DP, and Cantilena LR (1993c) The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 53:630-636.
16. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
17. Koley AP, Buters JT, Robinson RC, Markowitz A, and Friedman FK (1997) Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone. J Biol Chem 272:3149-3152.
18. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, and Fukuoka M (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16:1068-1074.
19. Kuppens IE, Beijnen J, and Schellens JH (2004) Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clin Colorectal Cancer 4:163-180.
20. Maenpaa J, Hall SD, Ring BJ, Strom SC, and Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
21. Mathijssen RH, de Jong FA, and van Schaik RH (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592.
22. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, and McLeod HL (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246-3253.
23. McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ, and Hutchison M (2005) Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 35:39-50.
24. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, and Taguchi T (1991) Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168.
25. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
26. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, et al. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412.
27. Sakuma T, Takai M, Endo Y, Kuroiwa M, Ohara A, Jarukamjorn K, Honma R, and Nemoto N (2000) A novel female-specific member of the CYP3A gene subfamily in the mouse liver. Arch Biochem Biophys 377:153-162.
28. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, et al. (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:2012-2020.
29. Schrag ML and Wienkers LC (2001) Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab Dispos 29:70-75.
30. Schwab GE, Raucy JL, and Johnson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33:493-499.
31. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
32. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ 3rd, Gilbertson R, Germain GS, et al. (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491-7499.
33. Ueng YF, Kuwabara T, Chun YJ, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
34. Villikka K, Kivisto KT, and Neuvonen PJ (1999) The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 65:377-381.
35. Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA, and Green LR (1994) Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 48:659-666.
36. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science (Wash DC) 305:683-686.
37. Zhang QY, Dunbar D, and Kaminsky LS (2003) Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos 31:1346-1351.